Back to Search Start Over

SAT-533 Men with Hypogonadism and Osteoporosis Benefit from Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU) Regardless of Co-Medication with Bisphosphonates: 10-Year Data from a Controlled Registry Study in a Urological Setting

Authors :
Abdulmaged M. Traish
Farid Saad
Gheorghe Doros
Ahmad Haider
Karim Sultan Haider
Source :
Journal of the Endocrine Society
Publication Year :
2019
Publisher :
The Endocrine Society, 2019.

Abstract

Background: Testosterone and its metabolite estradiol are essential factors in bone metabolism, and hypogonadism is an established risk factor for osteoporosis. Material and Methods: In a registry study of otherwise unselected men with hypogonadism in a urological office, 102 of 805 patients (13%) had osteoporosis diagnosed and treated elsewhere. 69 received TTh with TU 1000 mg/12 weeks (T-group). 33 had opted against TTh and served as controls (CTRL). BMD was measured at least once a year by using a whole body dual-energy X-ray densitometer (Norland XR-800). 10-year data are reported. Changes over time between groups were compared by mixed effects model for repeated measures with random effect for intercept and fixed effects for time, group and their interaction, and adjusted for age, weight, waist circumference, fasting glucose, blood pressure and lipids to account for baseline differences between groups. Results: Baseline age: 54.5±8.2 (T-group), 64.9±4.1 years (CTRL). Mean (median) follow-up was 7.5±2.3 (8) years in the T-group and 8.9±1.1 (9) years in CTRL. 36 (52%) in the T-group had Klinefelter’s syndrome (KS) which, in the majority of cases, was diagnosed secondary to the diagnosis of osteoporosis. 7 patients had primary hypogonadism other than KS, 6 had a history of alcohol abuse, 4 had Crohn’s disease, and 3 had had a kidney transplant. All patients were on Vitamin D-calcium supplements. 64 patients (93%) in the T-group and 23 (70%) in CTRL were on bisphosphonates at baseline. 11 patients (16%) in the T-group and 11 (33%) in CTRL discontinued bisphosphonates due to side effects. T-scores progressively improved from -3.39±0.56 to -1.19±0.03 after 10 years (T-group) and worsened from -3.01±0.3 to -3.83±0.53 in CTRL, adjusted difference between groups: 2.45 (p

Details

ISSN :
24721972
Volume :
3
Database :
OpenAIRE
Journal :
Journal of the Endocrine Society
Accession number :
edsair.doi.dedup.....7f723239d76891b588f1760f711a3f5a
Full Text :
https://doi.org/10.1210/js.2019-sat-533